PF06869206
PF06869206 性质
沸点 | 599.2±50.0 °C(Predicted) |
---|---|
密度 | 1.57±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | DMF:1mg/mL;二甲基亚砜:1mg/mL;乙醇:10mg/mL;乙醇:PBS (pH 7.2) (1:3): 0.25 mg/mL |
形态 | 结晶固体 |
酸度系数(pKa) | 11.78±0.40(Predicted) |
颜色 | 白色至米白色 |
PF06869206 用途与合成方法
IC50: 380 nM (NaPi2a/SLC34A1)
PF-06869206 shows a balance of attributes with 380 nM NaPi2a inhibition potency, excellent subtype selectivity, and acceptable aqueous solubility (46 μM). PF-06869206 is profiled for potency in the rodent NaPi2a and NaPi2c cell lines. PF-06869206 shows comparable submicromolar activity for the human, rat, and mouse NaPi2a isoforms with IC 50 s of 0.4±0.047 μM and 0.54±0.099 μM for rat NaPi2a and mouse NaPi2a, respectively.
PF-06869206 is evaluated in rodent PK studies to determine suitability for in vivo pharmacology exploration. Results show moderate clearance in both rat and mouse. Oral bioavailability at 5 mg/kg is good in rat and moderate in mouse. At higher oral doses of 50 mg/kg, supraproportional increases in exposure are observed in both species, suggestive of saturation of clearance. PF-06869206 has moderate terminal elimination half-life (t 1/2 =1.35 h, and 0.75 h for Wistar-Han rats (10 mg/kg, iv), and C57BL6 mice (1 mg/kg, iv)). Furthermore, permeability is good (14×10 -6 cm/s), and rat liver microsome (RLM) clearance is low (<14 μL/min/mg; HLM=39 μL/min/mg).
PF06869206 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-112065 | PF06869206 | 2227425-05-8 | 5mg | 920 |
2024-11-08 | HY-112065 | PF06869206 | 2227425-05-8 | 10mg | 1480 |